GlassScriptPhysician profile
Inae Lim
NPI 1033756010
$9,844.08
in general payments reported to CMS, 2019-2025
31 companies · $1,510 in 2025
The $1,510 reported for 2025 was more than what 90% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,710 · 2022: $1,652 · 2023: $2,618 · 2024: $2,354 · 2025: $1,510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,439 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,439.38 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $1,655.37 | 2021-2025 | Afrezza |
| Novo Nordisk INC | $1,488.66 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,304.55 | 2021-2025 | Evenity, Prolia, Tepezza |
| Lilly USA, LLC | $1,065.29 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $869.62 | 2022-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $719.06 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $629.54 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $600.98 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Xeris Pharmaceuticals, INC. | $249.67 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Medtronic, INC. | $204.06 | 2023-2025 | Minimed 780g, Intellis Adaptivestim |
| Cequr Corporation | $168.39 | 2023-2025 | Cequr Simplicity |
| Astrazeneca Pharmaceuticals LP | $145.17 | 2021-2022 | |
| Horizon Therapeutics Plc | $100.71 | 2021-2023 | Tepezza |
| Abbott Laboratories | $94.96 | 2022-2025 | Freestyle Libre 3 |
| Ascendis Pharma Endocrinology INC | $85.18 | 2025 | Yorvipath |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $77.00 | 2025 | Jatenzo |
| Dexcom, INC. | $75.99 | 2024-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $71.53 | 2023-2025 | Omnipod |
| Amarin Pharma, INC. | $41.75 | 2021 | |
| Pfizer INC. | $28.51 | 2021-2022 | |
| Astellas Pharma US INC | $24.43 | 2023 | Veozah |
| Recordati_rare_diseases_inc. | $16.84 | 2022 | |
| Eusa Pharma (US) LLC | $16.84 | 2022 | |
| Radius Health, INC. | $16.73 | 2025 | Tymlos |
| Ascensia Diabetes Care US INC. | $16.25 | 2025 | |
| Ibsa Pharma INC. | $14.18 | 2025 | Flector, Licart, Tirosint |
| Merck Sharp & Dohme LLC | $13.81 | 2023 | Steglatro |
| Neurocrine Biosciences, INC. | $13.79 | 2024 | |
| Intuity Medical INC | $13.57 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Alexion Pharmaceuticals, INC. | $13.50 | 2025 | Strensiq |
| Travere Therapeutics, INC. | $8.15 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inae Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.